2-{1-[2-(4-Fluoro-phenyl)-2-oxo-ethyl]-piperidin-4-ylmethyl}-2,3-dihydro-isoindol-1-one

treatment of schizophrenia

Chemical Formula: C22H23FN2O2

Molecular Weight: 366.4

OTAVAchemicals Catalogue Number:   15380609

CAS Registry Number:  359625-79-9

Purity: >95%

Ref.: Expert Opinion on Emerging Drugs (2020), 25(2), 189-200

Abstract: CYR-101 (MIN-101, MT-210) is a compound with affinities for sigma-2 and 5-HT2A receptors and no direct dopamine affinities. In Vitro: CYR-101 is currently under phase II clinical trials for the treatment of schizophrenia. CYR-101 demonstrates statistically significant efficacy in reducing negative symptoms and good tolerability in stable schizophrenia patients. A statistically significant difference in Positive and Negative Syndrome Scale negative factor score is observed, with lower scores for the CYR-101 32 mg/day and 64 mg/day groups compared with the placebo group[1].

DOI: 10.1080/14728214.2020.1773792